当前位置: 首页 >> 检索结果
1661. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.
作者: Anat Yaskolka Meir.;Ehud Rinott.;Gal Tsaban.;Hila Zelicha.;Alon Kaplan.;Philip Rosen.;Ilan Shelef.;Ilan Youngster.;Aryeh Shalev.;Matthias Blüher.;Uta Ceglarek.;Michael Stumvoll.;Kieran Tuohy.;Camilla Diotallevi.;Urska Vrhovsek.;Frank Hu.;Meir Stampfer.;Iris Shai.
来源: Gut. 2021年70卷11期2085-2095页
To examine the effectiveness of green-Mediterranean (MED) diet, further restricted in red/processed meat, and enriched with green plants and polyphenols on non-alcoholic fatty liver disease (NAFLD), reflected by intrahepatic fat (IHF) loss.
1662. Pneumatic dilation for persistent dysphagia after antireflux surgery, a multicentre single-blind randomised sham-controlled clinical trial.
作者: Jeroen M Schuitenmaker.;Froukje B van Hoeij.;Marlies P Schijven.;Jan Tack.;José M Conchillo.;Eric J Hazebroek.;André J P M Smout.;Albert J Bredenoord.
来源: Gut. 2022年71卷1期10-15页
There is no evidence-based treatment for persistent dysphagia after laparoscopic fundoplication. The aim of this study was to evaluate the effect of pneumatic dilation on persistent dysphagia after laparoscopic fundoplication.
1663. NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.
作者: Mabrouka Salem.;Joanna Lecka.;Julie Pelletier.;Danielle Gomes Marconato.;Aline Dumas.;Luc Vallières.;Gaetan Brochu.;Bernard Robaye.;Christian Jobin.;Jean Sévigny.
来源: Gut. 2022年71卷1期43-54页
Nucleotides are danger signals that activate inflammatory responses via binding P2 receptors. The nucleoside triphosphate diphosphohydrolase-8 (NTPDase8) is an ectonucleotidase that hydrolyses P2 receptor ligands. We investigated the role of NTPDase8 in intestinal inflammation.
1664. Novel scheme for non-invasive gut bioinformation acquisition with a magnetically controlled sampling capsule endoscope.
作者: Zhen Ding.;Weijun Wang.;Kun Zhang.;Fanhua Ming.;Tianyi Yangdai.;Tao Xu.;Huiying Shi.;Yuhui Bao.;Hailing Yao.;Hangyu Peng.;Chaoqun Han.;Weiwei Jiang.;Jun Liu.;Xiaohua Hou.;Rong Lin.
来源: Gut. 2021年70卷12期2297-2306页
Intestinal flora and metabolites are associated with multiple systemic diseases. Current approaches for acquiring information regarding microbiota/metabolites have limitations. We aimed to develop a precise magnetically controlled sampling capsule endoscope (MSCE) for the convenient, non-invasive and accurate acquisition of digestive bioinformation for disease diagnosis and evaluation.
1666. Rescue of male fertility following faecal microbiota transplantation from alginate oligosaccharide-dosed mice.
作者: Cong Zhang.;Bohui Xiong.;Liang Chen.;Wei Ge.;Shen Yin.;Yanni Feng.;Zhongyi Sun.;Qingyuan Sun.;Yong Zhao.;Wei Shen.;Hongfu Zhang.
来源: Gut. 2021年70卷11期2213-2215页 1668. Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study).
作者: Brooks D Cash.;Mark R Fleisher.;Steven Fern.;Elizabeth Rajan.;Robyn Haithcock.;David M Kastenberg.;David Pound.;Neofytos P Papageorgiou.;Ignacio Fernández-Urién.;Ira J Schmelkin.;Douglas K Rex.
来源: Gut. 2021年70卷11期2115-2122页
Colon capsule endoscopy (CCE) has shown promise for colorectal neoplasia detection compared with optical colonoscopy (OC), but has not been compared with other screening tests in average risk screening patients.
1669. Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis.
作者: Luoyan Ai.;Yimeng Ren.;Mingming Zhu.;Shiyuan Lu.;Yun Qian.;Zhaofei Chen.;Antao Xu.
来源: Gut. 2021年70卷12期2261-2272页
As a canonical membrane tethering factor, the function of synbindin has been expanding and indicated in immune response. Here, we investigated the role of synbindin in the regulation of toll-like receptor 4 (TLR4) signalling and macrophage response to microbiota during colitis.
1670. Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett's carcinoma.
作者: Hanno Ehlken.;Rüdiger Schmitz.;Sabine Riethdorf.;Lutz Riethdorf.;Jenny Krause.;Karl-Frederick Karstens.;Jörg Schrader.;Fabrice Viol.;Anastasios Giannou.;William Sterlacci.;Michael Vieth.;Till Clauditz.;Christian Kähler.;Oliver Mann.;Jakob R Izbicki.;Samuel Huber.;Klaus Pantel.;Thomas Rösch.
来源: Gut. 2022年71卷2期277-286页
Endoscopic resection has been established as curative therapy for superficial cancer arising from Barrett's oesophagus (BE); recurrences are very rare. Based on a case series with unusual and massive early recurrences, we analyse the issue of tumour cell reimplantation.
1671. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
作者: Laura Rosa Mangiapane.;Annalisa Nicotra.;Alice Turdo.;Miriam Gaggianesi.;Paola Bianca.;Simone Di Franco.;Davide Stefano Sardina.;Veronica Veschi.;Michele Signore.;Sven Beyes.;Luca Fagnocchi.;Micol Eleonora Fiori.;Maria Rita Bongiorno.;Melania Lo Iacono.;Irene Pillitteri.;Gloria Ganduscio.;Gaspare Gulotta.;Jan Paul Medema.;Alessio Zippo.;Matilde Todaro.;Ruggero De Maria.;Giorgio Stassi.
来源: Gut. 2022年71卷1期119-128页
Cancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.
1672. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
作者: Gabriel Mezzano.;Adria Juanola.;Andres Cardenas.;Esteban Mezey.;James P Hamilton.;Elisa Pose.;Isabel Graupera.;Pere Ginès.;Elsa Solà.;Ruben Hernaez.
来源: Gut. 2022年71卷1期148-155页
Acute-on-chronic liver failure (ACLF) is characterised by acute decompensation of cirrhosis associated with organ failures. We systematically evaluated the geographical variations of ACLF across the world in terms of prevalence, mortality, aetiology of chronic liver disease (CLD), triggers and organ failures.
1673. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19.
作者: Yun Kit Yeoh.;Tao Zuo.;Grace Chung-Yan Lui.;Fen Zhang.;Qin Liu.;Amy Yl Li.;Arthur Ck Chung.;Chun Pan Cheung.;Eugene Yk Tso.;Kitty Sc Fung.;Veronica Chan.;Lowell Ling.;Gavin Joynt.;David Shu-Cheong Hui.;Kai Ming Chow.;Susanna So Shan Ng.;Timothy Chun-Man Li.;Rita Wy Ng.;Terry Cf Yip.;Grace Lai-Hung Wong.;Francis Kl Chan.;Chun Kwok Wong.;Paul Ks Chan.;Siew C Ng.
来源: Gut. 2021年70卷4期698-706页
Although COVID-19 is primarily a respiratory illness, there is mounting evidence suggesting that the GI tract is involved in this disease. We investigated whether the gut microbiome is linked to disease severity in patients with COVID-19, and whether perturbations in microbiome composition, if any, resolve with clearance of the SARS-CoV-2 virus.
1674. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
作者: Shuichi Aoki.;Koetsu Inoue.;Sebastian Klein.;Stefan Halvorsen.;Jiang Chen.;Aya Matsui.;Mohammad R Nikmaneshi.;Shuji Kitahara.;Tai Hato.;Xianfeng Chen.;Kazumichi Kawakubo.;Hadi T Nia.;Ivy Chen.;Daniel H Schanne.;Emilie Mamessier.;Kohei Shigeta.;Hiroto Kikuchi.;Rakesh R Ramjiawan.;Tyge Ce Schmidt.;Masaaki Iwasaki.;Thomas Yau.;Theodore S Hong.;Alexander Quaas.;Patrick S Plum.;Simona Dima.;Irinel Popescu.;Nabeel Bardeesy.;Lance L Munn.;Mitesh J Borad.;Slim Sassi.;Rakesh K Jain.;Andrew X Zhu.;Dan G Duda.
来源: Gut. 2022年71卷1期185-193页
Intrahepatic cholangiocarcinoma (ICC)-a rare liver malignancy with limited therapeutic options-is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of placental growth factor (PlGF) in ICC progression.
1675. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
作者: Jiang Li.;Xi Liang.;Jing Jiang.;Lingling Yang.;Jiaojiao Xin.;Dongyan Shi.;Yingyan Lu.;Jun Li.;Keke Ren.;Hozeifa Mohamed Hassan.;Jianing Zhang.;Pengcheng Chen.;Heng Yao.;Jiaqi Li.;Tianzhou Wu.;Linfeng Jin.;Ping Ye.;Tan Li.;Huafen Zhang.;Suwan Sun.;Beibei Guo.;Xingping Zhou.;Qun Cai.;Jiaxian Chen.;Xiaowei Xu.;Jianrong Huang.;Shaorui Hao.;Jinqiu He.;Shaojie Xin.;Di Wang.;Jonel Trebicka.;Xin Chen.;Jun Li.; .
来源: Gut. 2022年71卷1期163-175页
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics.
1676. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25 years now. The first clinical observations in patients with refractory Crohn's disease rapidly responding to infliximab prompted accelerated clinical development and approval for this indication. However, many questions remained unanswered when this treatment came to market related to maintenance schedules, pharmacokinetics, toxicity and positioning. Many of these open questions were addressed by investigators and sponsors during more than two decades of clinical use. The authors were among the first to use infliximab in Crohn's disease and felt that now is a good time to look back and draw lessons from the remarkable anti-TNF story. Even today, new insights continue to appear. But more importantly, what was learnt in the past 25 years has created a platform for future development of even stronger and safer therapies. We should not forget to learn from the past.
1677. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers.
作者: Peter Georgeson.;Bernard J Pope.;Christophe Rosty.;Mark Clendenning.;Khalid Mahmood.;Jihoon E Joo.;Romy Walker.;Ryan A Hutchinson.;Susan Preston.;Julia Como.;Sharelle Joseland.;Aung Ko Win.;Finlay A Macrae.;John L Hopper.;Dmitri Mouradov.;Peter Gibbs.;Oliver M Sieber.;Dylan E O'Sullivan.;Darren R Brenner.;Steve Gallinger.;Mark A Jenkins.;Ingrid M Winship.;Daniel D Buchanan.
来源: Gut. 2021年70卷11期2138-2149页
Germline pathogenic variants (PVs) in the DNA mismatch repair (MMR) genes and in the base excision repair gene MUTYH underlie hereditary colorectal cancer (CRC) and polyposis syndromes. We evaluated the robustness and discriminatory potential of tumour mutational signatures in CRCs for identifying germline PV carriers.
1678. Endoscopes used in positive and critically ill patients are SARS-CoV-2 negative at virological assessment.
作者: Ivo Boškoski.;Anna Di Gemma.;Maria Valeria Matteo.;Fabio Grilli.;Paola Cattani.;Guido Costamagna.
来源: Gut. 2021年70卷9期1629-1631页
The risk of SARS-CoV-2 transmission in endoscopy is not only between patients and endoscopy staff but is also through inadequately reprocessed endoscopes. There are no studies that could confirm the efficacy of current ways of endoscope reprocessing on the elimination of SARS-CoV-2. The aim of this pilot study was to evaluate the efficacy of high disinfection of endoscopes with peracetic acid on eliminating SARS-CoV-2, but surprisingly we found that the virus cannot be detected on any part of endoscopes used in critically ill patients due to SARS-CoV-2 and this was the same for all types of endoscopies and procedures. If confirmed in larger studies, these findings will probably open a new scenario in the overall understanding of the real impact of the virus.
1679. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
作者: Chen-Hua Liu.;Chi-Yi Chen.;Wei-Wen Su.;Kuo-Chih Tseng.;Ching-Chu Lo.;Chun-Jen Liu.;Jyh-Jou Chen.;Cheng-Yuan Peng.;Yu-Lueng Shih.;Sheng-Shun Yang.;Chia-Sheng Huang.;Ke-Jhang Huang.;Chi-Yang Chang.;Ming-Chang Tsai.;Wei-Yu Kao.;Yo-Jen Fang.;Po-Yueh Chen.;Pei-Yuan Su.;Chih-Wei Tseng.;Jow-Jyh Huang.;Pei-Lun Lee.;Hsueh-Chou Lai.;Tsai-Yuan Hsieh.;Chung-Hsin Chang.;Yi-Jie Huang.;Fu-Jen Lee.;Chun-Chao Chang.;Jia-Horng Kao.
来源: Gut. 2022年71卷1期176-184页
Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5.
1680. Serotonin is elevated in COVID-19-associated diarrhoea.
作者: Seeun Ha.;Byungchang Jin.;Brooke Clemmensen.;Paul Park.;Sumaiya Mahboob.;Vadim Gladwill.;Farah Madhani Lovely.;Andres Gottfried-Blackmore.;Aida Habtezion.;Subhash Verma.;Seungil Ro.
来源: Gut. 2021年70卷10期2015-2017页 |